目次

Table of Content

1. RESEARCH METHODOLOGY

2. Introduction To CD123 Targeting Therapies
2.1 Introduction
2.2 History and Evolution

3. Scientific and Biological Insight
3.1 Structure, Biology and Significance Of CD123 (IL-3Randalpha;)
3.2 Rationale For Targeting CD123
3.3 CD123 As Biomarker

4. Therapeutic Approaches Targeting CD123
4.1 Fusion Proteins
4.2 Antibodies
4.3 Antibody Drug Conjugates
4.4 Cell Therapies
4.5 Therapeutic Peptides

5. Global CD123 Targeting Therapies Development Trends By Indication
5.1 Leukemia
5.2 Blastic Plasmacytoid Dendritic Cell Neoplasm
5.3 Myeloproliferative Neoplasms
5.4 Other Indications

6. CD123 Targeting Therapies Development Technology Platforms

7. Global CD123 Targeting Therapies Market Analysis
7.1 Current Market Scenario
7.2 Future Market Opportunity

8. Elzonris Clinical and Commercial Insight
8.1 Overview
8.2 Pricing and Dosage
8.3 Coverage and Reimbursement Scenario

9. CD123 Targeting Therapies Clinical Trials Overview
9.1 By Company
9.2 By Country
9.3 By Indication
9.4 By Phase
9.5 By Priority Status

10. Global CD123 Targeting Therapies Clinical Pipeline Overview By Company, Country, Indication and Phase
10.1 Preclinical
10.2 Phase I
10.3 Phase I/II
10.4 Phase II

11. Marketed CD123 Targeting Therapy Clinical Insight

12. Global CD123 Targeting Therapies Market Dynamics
12.1 Market Drivers and Opportunities
12.2 Market Challenges and Restraints

13. Competitive Landscape
13.1 AbbVie
13.2 Affimed
13.3 Aptevo Therapeutics
13.4 Arcellx
13.5 AstraZeneca
13.6 AvenCell Therapeutics
13.7 CSL Limited
13.8 Essen Biotech
13.9 Innate Pharma
13.10 Lava Therapeutics
13.11 Macrogenics
13.12 Molecular Partners
13.13 Stemline Therapeutics
13.14 Vincerx Pharma

List of Figures & Tables
Figure 2-1: Evolution of CD123-Targeted Therapies
Figure 3-1: CD123 - Expression Levels Across Cell Types
Figure 3-2: CD123 - Expression In Normal vs. Malignant Stem Cells
Figure 3-3: CD123 Targeted Therapies - Overview
Figure 3-4: CD123 As Biomarker For Patient Stratification
Figure 4-1: CD123 Targeting Fusion Protein - Structure
Figure 4-2: CD123 Fusion Proteins - Mechanism Of Action
Figure 4-3: CD123 Targeting Antibodies - Mechanism Of Action
Figure 4-4: CD123 Targeting ADCs - Structure and Mechanism Of Action
Figure 4-5: CD123 CAR T Cells
Figure 4-6: Therapeutic Peptides - Mechanism of Action
Figure 5-1: Leukemia - CD123 Driven Signaling Pathway
Figure 5-2: CD123 - Expression Across Leukemia Subtypes
Figure 5-3: AFM28-101 Phase 1 (NCT05817058) Trial - Study Initiation and Completion Year
Figure 5-4: Vibecotamab Phase 2 (NCT05285813) Trial - Study Initiation and Completion Year
Figure 5-5: CART123 Phase 1 (NCT03766126) Trial - Study Initiation and Completion Year
Figure 5-6: VNC-943-101 Phase 1 (NCT06034275) Trial - Study Initiation and Completion Year
Figure 5-7: CP-MGD024-01 Phase 1 (NCT05362773) Trial - Study Initiation and Completion Year
Figure 5-8: TAGVEN Phase 2 (NCT07007052) Trial - Study Initiation and Completion Year
Figure 5-9: Tagraxofusp Phase 2 (NCT04216524) Trial - Study Initiation and Completion Year
Figure 5-10: IMGN632-0801 Phase 1/2 (NCT03386513) Trial - Study Initiation and Completion Year
Figure 5-11: UHKT-CAR123-01 Early Phase 1 (NCT06765876) Trial - Study Initiation and Completion Year
Figure 5-12: PBC065 Phase 1 (NCT06690827) Trial - Study Initiation and Completion Year
Figure 5-13: STUDY00160238 Phase 1 (NCT06414681) Trial - Study Initiation and Completion Year
Figure 5-14: HSR210434 Phase 1 (NCT05233618) Trial - Study Initiation and Completion Year
Figure 5-15: Tagraxofusp Phase 1/2 (NCT05038592) Trial - Study Initiation and Completion Year
Figure 5-16: IMGN632-0801 Phase 1/2 (NCT03386513) Trial - Study Initiation and Completion Year
Figure 5-17: Flotetuzumab Phase 1 (NCT04681105) Trial - Study Initiation and Completion Year
Figure 6-1: ICE Platform - Affimed
Figure 6-2: ADAPTIR - Aptevo Therapeutics
Figure 6-3: ARC-SparX - Arcellx
Figure 6-4: Universal Targeting Platform - AvenCell
Figure 6-5: ANKET - Innate Pharma
Figure 6-6: GAMMABODYandreg; Platform - LAVA Therapeutics
Figure 6-7: GAMMABODYandreg; Platform Mechanism - LAVA Therapeutics
Figure 6-8: DART Platform - MacroGenics
Figure 6-9: VersAptx - Vincerx Pharma
Figure 7-1: CD123 Targeted Therapy Market - Future Opportunities
Figure 8-1: Elzonris - Price Per Vial By Region (US$), July’2025
Figure 9-1: Global - CD123 Targeting Therapy Clinical Pipeline By Company (Number Of Therapies), 2025
Figure 9-2: Global - CD123 Targeting Therapy Clinical Pipeline By Country (Number Of Therapies), 2025
Figure 9-3: Global - CD123 Targeting Therapy Clinical Pipeline By Indication (Number Of Therapies), 2025
Figure 9-4: Global - CD123 Targeting Therapy Clinical Pipeline By Phase (Number Of Therapies), 2025
Figure 9-5: Global - CD123 Targeting Therapy Clinical Pipeline By Priority Status (Number Of Therapies), 2025
Figure 12-1: CD123 Targeted Therapy Market - Drivers and Opportunities
Figure 12-2: CD123 Targeted Therapy Market - Challenges and Restraints
Table 8-1: Elzonris - Recommended Dosage Modifications
Table 8-2: Elzonris - CLS Management Guidelines